1-20 of 217
Nizar J Bahlis
Close
Save search
Follow your search
Access your saved searches in your account
Would you like to receive an alert when new items match your search?
Close Modal
Sort by
Journal Articles

Impact of soluble BCMA and non–T-cell factors on refractoriness to BCMA-targeting T-cell engagers in multiple myeloma

CME
Holly Lee, Michael Durante, Sheri Skerget, Deeksha Vishwamitra, Sacha Benaoudia, Sungwoo Ahn, Mansour Poorebrahim, Elie Barakat, David Jung, Noémie Leblay, Bachisio Ziccheddu, Benjamin Diamond, Marios Papadimitriou, Adam D. Cohen, Ola Landgren, Paola Neri, Francesco Maura, Nizar J. Bahlis
Journal: Blood
Blood (2024) 144 (25): 2637–2651.
https://doi.org/10.1182/blood.2024026212
Published: 2024
Includes: Supplemental data
Journal Articles

Efficacy and safety of teclistamab in patients with relapsed/refractory multiple myeloma after BCMA-targeting therapies

Clinical Trials & Observations
Cyrille Touzeau, Amrita Y. Krishnan, Philippe Moreau, Aurore Perrot, Saad Z. Usmani, Salomon Manier, Michele Cavo, Carmen Martinez Chamorro, Ajay K. Nooka, Thomas G. Martin, Lionel Karlin, Xavier Leleu, Nizar J. Bahlis, Britta Besemer, Lixia Pei, Sarah Stein, Shun Xin Wang Lin, Danielle Trancucci, Raluca I. Verona, Suzette Girgis, Xin Miao, Clarissa M. Uhlar, Katherine Chastain, Alfred L. Garfall
Journal: Blood
Blood (2024) 144 (23): 2375–2388.
https://doi.org/10.1182/blood.2023023616
Published: 2024
Includes: Supplemental data
Journal Articles

Ide-cel vs standard regimens in triple-class–exposed relapsed and refractory multiple myeloma: updated KarMMa-3 analyses

Clinical Trials & Observations
Sikander Ailawadhi, Bertrand Arnulf, Krina Patel, Michele Cavo, Ajay K. Nooka, Salomon Manier, Natalie Callander, Luciano J. Costa, Ravi Vij, Nizar J. Bahlis, Philippe Moreau, Scott Solomon, Ingerid Weum Abrahamsen, Rachid Baz, Annemiek Broijl, Christine Chen, Sundar Jagannath, Noopur Raje, Christof Scheid, Michel Delforge, Reuben Benjamin, Thomas Pabst, Shinsuke Iida, Jesús Berdeja, Sergio Giralt, Anna Truppel-Hartmann, Yanping Chen, Xiaobo Zhong, Fan Wu, Julia Piasecki, Laurie Eliason, Devender Dhanda, Jasper Felten, Andrea Caia, Mark Cook, Mihaela Popa McKiver, Paula Rodríguez-Otero
Journal: Blood
Blood (2024) 144 (23): 2389–2401.
https://doi.org/10.1182/blood.2024024582
Published: 2024
Includes: Supplemental data
Journal Articles

Mezigdomide (MEZI) in Novel-Novel Combinations for Relapsed or Refractory Multiple Myeloma (RRMM): Preliminary Results from the CA057-003 Trial

Luciano J. Costa, Fredrik Schjesvold, Rakesh Popat, David Siegel, Saad Z. Usmani, Syed Abbas Ali, Michael P. Chu, Monique A. Hartley-Brown, Nizar J. Bahlis, Albert Oriol, Joaquín Martínez Lopez, Enrique M. Ocio, Karthik Ramasamy, Donna Reece, Emma Searle, Allison Gaudy, Antonina Kurtova, Wen Zhang, Rafael Sarmiento, August Dietrich, Jessica Katz, Michael Pourdehnad, Paul G. Richardson
Journal: Blood
Blood (2024) 144 (Supplement 1): 677.
https://doi.org/10.1182/blood-2024-198403
Published: 2024
Journal Articles

Genomic Determinants of Resistance to Anti-BCMA Chimeric Antigen Receptor T-Cell (CART) Therapies in Patients with Relapsed/Refractory Multiple Myeloma

Francesco Maura, Ciara Louise Freeman, Holly Lee, Kylee H Maclachlan, Michael Durante, Bachisio Ziccheddu, Meghan Menges, Benjamin Diamond, Marios Papadimitriou, Ariosto Siqueira Silva, Praneeth Reddy Sudalagunta, Noemie Leblay, Sungwoo Ahn, Ethan Fuller, Edward Briercheck, Phaedra Agius, Doris K. Hansen, Xiaofei Song, Xiaohong Zhao, Mark B. Meads, Jamie Teer, Ross S Firestone, Juan-Jose Garces, Tomas Jelinek, Rachid Baz, Melissa Alsina, Anusuyam Ramasubramanian, Eric Smith, Sergio Giralt, Sham Mailankody, Paola Neri, Saad Z. Usmani, Frederick Locke, Nizar J. Bahlis, Ola Landgren, Kenneth H. Shain
Journal: Blood
Blood (2024) 144 (Supplement 1): 247.
https://doi.org/10.1182/blood-2024-201288
Published: 2024
Journal Articles

Phase 3 Randomized Study of Daratumumab (DARA) + Bortezomib, Lenalidomide and Dexamethasone (VRd) Versus Alone in Patients with Transplant-Ineligible Newly Diagnosed Multiple Myeloma or for Whom Transplant Is Not Planned As Initial Therapy: Analysis of Minimal Residual Disease in the Cepheus Trial

Sonja Zweegman, Thierry Facon, Vania Hungria, Nizar J. Bahlis, Christopher P. Venner, Marc Braunstein, Luděk Pour, Josep Marti Tutusaus, Supratik Basu, Yael C. Cohen, Morio Matsumoto, Kenshi Suzuki, Cyrille Hulin, Sebastian Grosicki, Wojciech Maciej Legiec, Meral Beksac, Angelo Maiolino, Hiroyuki Takamatsu, Aurore Perrot, Mehmet Turgut, Weiping Liu, Jianping Wang, Katherine Chastain, Jessica Vermeulen, Maria Krevvata, Lorena Lopez-Masi, Jodi Carey, Melissa Rowe, Robin Carson, Saad Z. Usmani
Journal: Blood
Blood (2024) 144 (Supplement 1): 362.
https://doi.org/10.1182/blood-2024-200871
Published: 2024
Journal Articles

The Effect of Elranatamab on Patient-Reported Outcomes in Patients with Relapsed/Refractory Multiple Myeloma Naïve and Exposed to B-Cell Maturation Antigen (BCMA)-Directed Therapies: Updated Follow-Up from the MagnetisMM-3 Study

Mohamad Mohty, Nizar J. Bahlis, Ajay K. Nooka, Marco DiBonaventura, Joseph C. Cappelleri, Umberto Conte
Journal: Blood
Blood (2024) 144 (Supplement 1): 1933.
https://doi.org/10.1182/blood-2024-203723
Published: 2024
Journal Articles

BCMA Extracellular Domain Functional Hotspots and Resistance to Variable Anti-BCMA T Cell Engagers in Multiple Myeloma

Holly Lee, David Jung, Mansour Poorebrahim, Sacha Benaoudia, Sungwoo Ahn, Noémie Leblay, Eric Letouzé, Philippe Moreau, Herve Avet-Loiseau, Leo Rasche, Jonathan J Keats, Francesco Maura, Paola Neri, Nizar J. Bahlis
Journal: Blood
Blood (2024) 144 (Supplement 1): 4651.
https://doi.org/10.1182/blood-2024-211833
Published: 2024
Journal Articles

Immune and Tumor Mediators of Resistance to Daratumumab-IMiDs Based Therapies in Relapsed Multiple Myeloma

Noémie Leblay, Sungwoo Ahn, Holly Lee, Matteo Claudio Da Vià, Mansour Poorebrahim, Sacha Benaoudia, David Jung, Elham Hasheminasabgorji, Niccolò Bolli, Nizar J. Bahlis, Paola Neri
Journal: Blood
Blood (2024) 144 (Supplement 1): 4642.
https://doi.org/10.1182/blood-2024-208842
Published: 2024
Journal Articles

Cevostamab in Patients with Heavily Pretreated Relapsed/Refractory Multiple Myeloma (RRMM): Updated Results from an Ongoing Phase I Study Demonstrate Clinically Meaningful Activity and Manageable Safety and Inform the Doses and Regimen for Combination Studies

Joshua Richter, Sheeba K. Thomas, Amrita Y Krishnan, Jacob P. Laubach, Adam D. Cohen, Suzanne Trudel, Luciano J. Costa, Nizar J. Bahlis, Peter A. Forsberg, Rayan Kaedbey, Rafael Fonseca, Andrew Spencer, Paula Rodríguez-Otero, Maria-Victoria Mateos, Chihunt Wong, James Cooper, Tulika Tyagi, Rin Nakamura, Voleak Choeurng, Alexander M. Lesokhin
Journal: Blood
Blood (2024) 144 (Supplement 1): 1021.
https://doi.org/10.1182/blood-2024-199542
Published: 2024
Journal Articles

Efficacy and Safety of Selinexor, Pomalidomide, and Dexamethasone (SPd) for Treatment of Patients with Relapsed or Refractory Multiple Myeloma (RRMM)

Muhamed Baljevic, Nizar J. Bahlis, Rami Kotb, Gary J. Schiller, Brea Lipe, Sumit Madan, Heather J. Sutherland, Suzanne Lentzsch, Natalie Callander, Noa Biran, Dane Van Domelen, Tomer Mark, Darrell White
Journal: Blood
Blood (2024) 144 (Supplement 1): 1996.
https://doi.org/10.1182/blood-2024-208086
Published: 2024
Journal Articles

Pharmacodynamic Signatures and Correlatives of Response in Patients with Relapsed/Refractory Multiple Myeloma (RRMM) Treated with Talquetamab or Teclistamab Plus Daratumumab and Pomalidomide

Deeksha Vishwamitra, Sheri Skerget, Diana Cortes, Kalpana Bakshi, Lien Vandenberk, Weili Sun, Jaszianne Tolbert, Colleen Kane, Hein Ludlage, Bas D Koster, Julie S Larsen, Tobias Kampfenkel, Ching Li, Farheen Zishan, Thomas Prior, Luciano J. Costa, Jesus G Berdeja, Cyrille Touzeau, Aurore Perrot, Emma Searle, Jeffrey V Matous, Ajai Chari, Donna Reece, Manisha Bhutani, Bhagirathbhai Dholaria, Anita D'Souza, Thomas G Martin, John T. McKay, Alfred L Garfall, Amrita Y Krishnan, Niels W.C.J. van de Donk, Nizar J. Bahlis, Ricardo M. Attar
Journal: Blood
Blood (2024) 144 (Supplement 1): 594.
https://doi.org/10.1182/blood-2024-200300
Published: 2024
Journal Articles

Convergent Evolution Towards CD38 Biallelic Loss Is a Recurrent Mechanism of Resistance to Anti-CD38 Antibodies in Multiple Myeloma

Benjamin Diamond, Linda B. Baughn, Mansour Poorebrahim, Alexandra Maria Poos, Holly Lee, Marcella Kaddoura, J Erin Wiedmeier-Nutor, Michael Durante, Gregory Otteson, Dragan Jevremovic, Hongwei Tang, Stefan Frohling, Marios Papadimitriou, Bachisio Ziccheddu, Tomas Jelinek, Ola Landgren, Paola Neri, P. Leif Bergsagel, Esteban Braggio, Shaji Kumar, Marc S. Raab, Rafael Fonseca, Nizar J. Bahlis, Niels Weinhold, Francesco Maura
Journal: Blood
Blood (2024) 144 (Supplement 1): 592.
https://doi.org/10.1182/blood-2024-201056
Published: 2024
Journal Articles

NF-Kb Pathway Activation Driven By TRAF3 Loss Mediates Resistance to Anti-BCMA T-Cell Based Therapies in Multiple Myeloma

David Jung, Holly Lee, Sejal Chikhale, Mansour Poorebrahim, Sungwoo Ahn, Sacha Benaoudia, Noemie Leblay, Francesco Maura, Nizar J. Bahlis, Paola Neri
Journal: Blood
Blood (2024) 144 (Supplement 1): 591.
https://doi.org/10.1182/blood-2024-206347
Published: 2024
Journal Articles

Biomarker Analyses of the CC-92480-MM-001 Trial to Guide Combinatorial Strategies for Mezigdomide

Tracy T. Chow, Nicholas Stong, Saleh Tamim, Chad C. Bjorklund, Antonina Kurtova, Keyur Desai, Joseph T. Hadala, Cynthia Donahue, Phillip Koo, Yue Zhu, Jessica Katz, Anita K. Gandhi, Suzanne Trudel, Nizar J. Bahlis, Paul G. Richardson, Michael Amatangelo
Journal: Blood
Blood (2024) 144 (Supplement 1): 3261.
https://doi.org/10.1182/blood-2024-199019
Published: 2024
Journal Articles

Timing Antigenic Escape in Multiple Myeloma Treated with T-Cell Redirecting Immunotherapies

Marios Papadimitriou, Sungwoo Ahn, Benjamin Diamond, Holly Lee, John McIntyre, Marietta Truger, Michael Durante, Bachisio Ziccheddu, Ola Landgren, Leo Rasche, Nizar J. Bahlis, Paola Neri, Francesco Maura
Journal: Blood
Blood (2024) 144 (Supplement 1): 1899.
https://doi.org/10.1182/blood-2024-212294
Published: 2024
Journal Articles

Tumor Intrinsic and Antigen-Independent Resistance Mechanisms to Bispecific T Cell Engagers in Multiple Myeloma

Holly Lee, Sungwoo Ahn, Mansour Poorebrahim, David Jung, Sacha Benaoudia, Noémie Leblay, Francesco Maura, Lawrence H. Boise, Paola Neri, Nizar J. Bahlis
Journal: Blood
Blood (2024) 144 (Supplement 1): 1892.
https://doi.org/10.1182/blood-2024-211979
Published: 2024
Journal Articles

MagnetisMM-3: Long-Term Update and Efficacy and Safety of Less Frequent Dosing of Elranatamab in Patients with Relapsed or Refractory Multiple Myeloma

H. Miles Prince, Nizar J. Bahlis, Paula Rodríguez-Otero, Lionel Karlin, Luke Akard, Asya Varshavsky-Yanovsky, Michael P. Chu, Yuya Nagai, David H. Vesole, Anne Hickman, Sharon T. Sullivan, Eric Leip, Umberto Conte, Andrea Viqueira, Alexander M. Lesokhin
Journal: Blood
Blood (2024) 144 (Supplement 1): 4738.
https://doi.org/10.1182/blood-2024-208192
Published: 2024
Journal Articles

Correlation of immune fitness with response to teclistamab in relapsed/refractory multiple myeloma in the MajesTEC-1 study

Clinical Trials & Observations
Diana Cortes-Selva, Tatiana Perova, Sheri Skerget, Deeksha Vishwamitra, Sarah Stein, Rengasamy Boominathan, Onsay Lau, Karl Calara-Nielsen, Cuc Davis, Jaymala Patel, Arnob Banerjee, Tara Stephenson, Clarissa Uhlar, Rachel Kobos, Jenna Goldberg, Lixia Pei, Danielle Trancucci, Suzette Girgis, Shun Xin Wang Lin, Liviawati S. Wu, Philippe Moreau, Saad Z. Usmani, Nizar J. Bahlis, Niels W. C. J. van de Donk, Raluca I. Verona
Journal: Blood
Blood (2024) 144 (6): 615–628.
https://doi.org/10.1182/blood.2023022823
Published: 2024
Includes: Supplemental data
Journal Articles

Smoldering multiple myeloma: taking the narrow over the wide path?

Herve Avet-Loiseau, Nizar J. Bahlis
Journal: Blood
Blood (2024) 143 (20): 2025–2028.
https://doi.org/10.1182/blood.2024023880
Published: 2024